Grifols GRFS NASDAQ · Healthcare · Spain
$8.47 -1.85% -$0.16
Summary
60 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 23% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- Repaying its net debt would take 4.8 years of operating profit.
- It missed profit estimates 4 times in the last 8 quarters.
- It earns only 5.6 EUR a year on every 100 EUR of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 12.7 EUR for 1 EUR of yearly profit. Over the last five years it was 55.6 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 6.2% a year over 5 years. Over the last 3 years it grew by 6.0% a year. Earnings per share grew by 23% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 63 EUR
- Research and development 5.3 EUR
- Sales and administration 15 EUR
- Taxes and other 10 EUR
- Net profit 6.8 EUR
Net profit, industry median (Drug Manufacturers - General) 15 EUR
Out of every 100 EUR of revenue, 6.8 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 12.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.12%
- Paid out of profit
- 14%
You receive $0.09 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 2
- Sell 2
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Haemoderivatives 86%
- Transfusional medicine 8.3%
- Other Product 3.2%
- Bio supplies 2.0%
- Other diagnostic 0.2%
By region
- USA and Canada. 60%
- Rest of the world 23%
- Rest of European Union 17%
Haemoderivatives brings in 86% of revenue. Other Product grew fastest, by 57% a year.
Segments in detail